Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $75000.0.

  • BioXcel Therapeutics' Depreciation & Amortization (CF) fell 259.74% to $75000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $303000.0, marking a year-over-year decrease of 225.81%. This contributed to the annual value of $309000.0 for FY2024, which is 283.02% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $75000.0 for Q3 2025, which was down 259.74% from $75000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $85000.0 during Q3 2022, with a 5-year trough of $75000.0 in Q2 2025.
  • In the last 4 years, BioXcel Therapeutics' Depreciation & Amortization (CF) had a median value of $78000.0 in 2023 and averaged $78666.7.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Depreciation & Amortization (CF) was 389.61% (2023), while the steepest drop was 705.88% (2023).
  • Over the past 4 years, BioXcel Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $81000.0 in 2022, then fell by 3.7% to $78000.0 in 2023, then dropped by 1.28% to $77000.0 in 2024, then fell by 2.6% to $75000.0 in 2025.
  • Its last three reported values are $75000.0 in Q3 2025, $75000.0 for Q2 2025, and $76000.0 during Q1 2025.